Looking to make a splash at JPMorgan, Eli Lilly rushed to put its $8B buyout deal together for Loxo in 10 days

Eli Lilly execs were in a rush when they sat down with Loxo CEO Josh Bilenker 5 days ahead of last Christmas. They wanted to buy his company and were prepared to pay $230 a share. But it had to be done now; CEO Dave Ricks wanted to announce the buyout on the morning of January 7, just as the annual JPMorgan confab got underway.

David Ricks They got their deal. Ten days later they had Ricks' take-it-or-leave it offer of $235 — $8 billion in cash — on the table. And Bilenker and his board took it. A week later, Lilly made their splash, as planned, without any of the usual back and forth involved as a biotech tries to negotiate the very best price — often by trying to ignite an auction.

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 47,400+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,400+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->